Fingerprint
Dive into the research topics of 'Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically